ArticleOpen access20261citation· Semantic Scholar
Cost-utility of first-line dostarlimab plus carboplatin-paclitaxel compared with placebo for patients with pA/rEC: a partitioned survival analysis
Health Economics Review · vol. 16 (1)
dostarlimabendometrial cancercarboplatin-paclitaxelcost-utility analysis
